Failure to seroconvert after three doses of inactivated COVID-19 vaccines in a patient co-infected with HBV and HIV: A case report

Figures & data

Figure 1. The HIV/HBV co-infected patient’s schedule of vaccination and blood collection.

Table 1. The HIV/HBV co-infected patient’s routine laboratory test results during vaccination.

Indicator	Reference range	March 3, 2021		June 8, 2021	October 25, 2021	January 6, 2022
CD4+T cell count (cells/µL)	500–1600		309	327	313	313
CD4+T ratio (%)	34–52		24.6	26.4	23.3	24.2
CD8+T cell count (cells/µL)	320–1250		492	523	519	529
CD8+T ratio (%)	21–39		39.2	42.3	38.6	40.9
CD4+T/CD8+T (-)	1.4–2.0		0.63	0.63	0.60	0.59
HIV VL (copies/mL)*	–		<50	<50	<50	<50

*The lower limit of detection is 50 copies/mL.

Figure 2. The S-RBD-IgG antibody levels of the participants during follow-up period.

Data availability statement

The data presented in this case report are available on request from the corresponding author. The data are not publicly available according to the ethical committee decision on the conduct of this study.